Benuvia Operations Awarded NIH Contract for GMP Synthesis of Psilocybin and Other Bulk Drug Substances

Contract to advance the research and development of new and innovative treatments for substance use disorders and mental health conditions

ROUND ROCK, Texas, March 25, 2025 /PRNewswire/ -- Benuvia Operations, LLC (Benuvia), a global contract development and manufacturing organization, today announced that it has been awarded a five-year contract by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), for the Good Manufacturing Practice (GMP) synthesis of psilocybin and other bulk drug substances.

The NIH contract will support the research and development of high-quality active pharmaceutical ingredients (APIs) for substance use disorders and mental health conditions. Benuvia will initially focus on the synthesis and scale-up of psilocybin, a Schedule I substance under the Controlled Substances Act that was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for major depressive disorder in 2019 and treatment-resistant depression in 2018. As part of the contract, Benuvia will manufacture and deliver GMP-grade psilocybin for NIDA's preclinical toxicity studies and clinical trials.

"This contract highlights our leadership in the development and manufacturing of controlled substances under GMP conditions," said Terry Novak, CEO of Benuvia. "We are honored to support NIH's efforts in advancing groundbreaking research into innovative therapies for substance use disorders and mental health conditions. Our state-of-the-art capabilities enable us to supply the highest-quality pharmaceutical compounds that meet the most rigorous regulatory standards."

Psilocybin is a naturally occurring psychedelic compound that comes from certain types of mushrooms. The drug is being evaluated in clinical studies as a potential treatment for many health disorders, including depression, anxiety, and substance use disorders. Historically, psilocybin's classification as a Schedule I controlled substance has limited its availability for research purposes. Through this NIH contract, Benuvia will produce psilocybin under stringent GMP conditions, ensuring researchers can access a consistent, pharmaceutical-grade product that meets both FDA and Drug Enforcement Administration (DEA) regulations.

Mr. Novak continued, "Our mission at Benuvia is to provide high-purity, federally approved substances for scientific research and pharmaceutical development. We look forward to working with the NIH to help evaluate psilocybin's therapeutic potential for the millions of patients suffering from these conditions."  

The contract is funded by the NIH under Contract No. 75N95025D00003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Benuvia Operations, LLC
Benuvia Operations, LLC is a global Contract Development and Manufacturing Organization (CDMO) that helps pharmaceutical, and biotech companies deliver life-changing therapies to patients in need. The company provides end-to-end development and manufacturing services for Active Pharmaceutical Ingredients (APIs) and finished dosage products and has extensive experience with cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000 square foot best-in-class manufacturing facility in Round Rock, Texas that can produce Schedule I-V compounds, offering comprehensive solutions for companies throughout the entire drug development lifecycle—from API synthesis and clinical trial supply to commercial production. Learn more at www.benuvia.com.

Forward-Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "anticipate", "believe", "could", "estimate", "upcoming", "expect", "intend", "may", "plan", "predict", "project", "will" and similar terms and phrases may be used to identify forward-looking statements in this press release. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. These forward-looking statements should be considered together with the risks and uncertainties discussed in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

Contact
KWM Communications
Kellie Walsh
(914) 315-6072
[email protected]

SOURCE Benuvia Operations, LLC